UNSPSC 51142513: Rasagiline

This classification denotes a monoamine oxidase inhibitor and antiparkinsonian agent with the molecular formula C12H13N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 003N66TS6T, chemically known as 2,3-dihydro-n-2-propynyl-1h-inden-1-amine but generally known as rasagiline, which bears US NIH Compound Identifier 122316. European Medicines Agency schedules Rasagiline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10261MIG.

UNSPSC 51142513 Rasagiline, a Commodity code, nominally designates a single Parkinson's disease medication, but recent state and local procurement activity under this code shows substantial mismatch. The three recent opportunities posted under 51142513 involve naloxone (opioid antagonist), direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and OTC products — none of which are rasagiline. State and local procurement offices appear to be using this code as a catch-all for pharmaceutical procurement rather than limiting it to the specific rasagiline molecule. The actual work being solicited includes volume purchases of finished pharmaceuticals and OTC products for distribution through established wholesaler networks, direct contracting arrangements with manufacturers to bypass pharmacy benefit managers, and community health initiatives focused on substance-use response. Issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing entities administering pooled procurement for state and local members (Minnesota Multistate Cooperative Purchasing Alliance, serving multiple states including Oregon).

Recent opportunities span Florida, Texas, and Minnesota, with the Minnesota MMCAP cooperative representing the broadest geographic footprint across multiple jurisdictions. Representative solicitations include Seminole County's IFB60459723LAS (IFB posted June 30, 2026, due July 26, 2023, for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries); Texas HHS's RFI HHS0017013 (posted April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional PBM channels); and MMCAP's S1070000015802 (RFP posted January 20, 2026, due March 26, 2026, for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, with contract effectiveness July 1, 2026). The code shows limited decision relevance for rasagiline specialists; vendors positioning for pharmaceutical procurement under this code should expect broad commodity pharmaceutical demand rather than single-indication specialty drugs.